The combination of treatment strategies used for patients suffering from advanced cases of lung cancer can cause a wide range of side effects. Spray drying is a useful particle engineering technique that can deliver particles within the necessary specifications and can be used to manufacture locally delivered dry powder inhaler treatments.
Three combination case studies are demonstrated, in which bevacizumab is paired with erlotinib, cisplatin, or paclitaxel in a dry powder inhaler formulation. The resulting formulations preserved the biologic activity of the antibody, achieved target drug concentration, and had aerosol properties suitable for pulmonary delivery.
A head-to-head comparison of spray-dried and jet-milled mannitol for respiratory delivery reveals opportunities and risks for designing a product based on each approach. This case study describes how to use risk assessments to inform engineering technology selection and illustrates how particle morphology affects aerodynamic performance.
Inhaled formulations are traditionally prepared by micronization and blending, but many APIs are not compatible with milling, including biologics. Gain insights into a “simul-spray” process pioneering for combining small and large molecules into a single, atomized drug product for inhalation administration.
This website uses cookies to ensure you get the best experience on our website. Learn more
